Introduction
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and its incidence is still on the rise [@B1]. In China, endemic hepatitis B virus (HBV) infection results in greater morbidity and mortality [@B2]. Although the overall survival of HCC has increased in the past decades, the multistep and multicentric carcinogenesis of HCC frequently leads to recurrence and impedes further improve of long-term prognosis [@B3]. Thus, early detection of HCC and its recurrence might provide additional chance to prolong the survival.

Currently, different biomarkers are used in the continuum of care of HCC, from diagnosis to disease surveillance [@B4]. Alpha fetoprotein (AFP) is the best-studied and the only serum biomarker undergone all five phases of biomarker development for HCC; other biomarkers including *Lens culinaris* agglutinin-reactive AFP (AFP-L3), Des-γ-carboxyprothrombin (DCP), Golgi Protein-73 (GP73), and Glypican 3 (GPC3) are still under investigation and require further validation [@B5]. However, the diagnostic performance of these biomarkers is unsatisfying: the cutoff value at 20 ng/ml of AFP for HCC detection yields sensitivity and specificity ranging from 41% to 65% and 80% to 94% respectively [@B6]. Therefore, novel biomarkers for early diagnosis and identification of recurrence are needed.

Recently, circulating tumor DNA (ctDNA) has attracted extensive attention for its wide utility in cancer research. ctDNAs are mutant DNAs released to the circulation by tumor cells and constitute part of circulating cell-free DNA (cfDNA) in different types of cancer [@B7]. With aberrantly genetic information harbored, ctDNA has been reported as liquid biopsy to profile the genome of tumor more comprehensively than conventional sampling method, thus qualifying it as a better vehicle to provide information for guiding targeted therapy [@B8], unveiling drug resistance [@B9], and monitoring treatment response [@B10]. Moreover, ctDNA is highly specific and could be detected at extremely low concentration, making it ideal for early diagnosis [@B11]. Analysis of ctDNA enabled efficient temporal assessment of disease status and early detection of incipient recurrence, providing an average of 10 months\' lead time on detection of metastatic recurrence than traditional modalities [@B12]; detectable ctDNA after resection could identify cancer patients at high risk of recurrence [@B13] and dynamic ctDNA change predicts clinical relapse [@B14].

Till now, few studies have evaluated the presence or features of ctDNA in HCC patients, let alone its potential translational significance. Hereby, we tried to investigate whether ctDNA could be detected by targeting hotspot mutations using droplet digital PCR (ddPCR) in HCC patients. Mutations in the plasma were first detected and then the tumor and adjacent liver tissues/peripheral blood mononuclear cells (PBMCs) were sequenced to identify the origin of these mutants. The evidence presented here demonstrated the feasibility of detecting ctDNA using ddPCR in HCC patients and provided evidence to support the clinical utility of ctDNA in the management of HCC.

Materials and Methods
=====================

Patients and sample collection
------------------------------

Patients treated at Zhongshan Hospital, Fudan University between October 2014 and March 2015 were enrolled if they had: 1, no previous histories of or synchronous malignancies in other organs; 2, no anti-tumor treatments of any forms prior to surgery; 3, histopathologically verified HCC. Ten milliliter blood was drawn from ulnar vein preoperatively and collected in EDTA tube (BD, Plymouth, UK). The primary tumor and matched adjacent liver tissues were dissected during operation and stored at -80 ^o^C until use. The clinicopathological information was retrieved from medical records. This study was approved by the Institutional Review Board of Zhongshan Hospital, Fudan University. Informed consent was obtained from individual patient.

Plasma separation and cfDNA extraction
--------------------------------------

Blood samples were processed within 3 h after venipuncture by a two-step centrifugation method: first spun at 3,000 rpm for 10 min to remove the majority of blood cells and a second spin at 14,000 rpm for another 10 min to remove the cellular debris. The plasma was subpackaged in aliquots of 1 ml and stored at -80 ^o^C until use. The blood cells after first centrifugation were used to separate PBMCs using Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden). The cfDNA was extracted using the QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Germany) with the QIAvac 24 Plus vacuum manifold, according to the manufacturer\'s instructions.

ddPCR
-----

The QX200 droplet digital PCR system (Bio-Rad, Hercules, USA) was used for mutant detection according to the manufacturer\'s instructions. The ddPCR reactions were carried out in 20 µl volumes using 10 µl 2x ddPCR SuperMix (Bio-Rad), 5 µl cfDNA template, 1 µl (20x) wild type probe/primer mix, 1µl (20x) mutant probe/primer mix, and 3µl deionized distilled water. Then each 20 µl reaction volume was carefully loaded into the well of Droplet Generator Cartridge (Bio-Rad) and 70 µl droplet generation oil (Bio-Rad) was subsequently loaded to generate droplets. The cartridge was covered with Droplet Generator Gasket (Bio-Rad) and transferred into QX200 Droplet Generator (Bio-Rad) to generate a maximum of 20,000 droplets from each sample. Then droplets from each sample were transferred into a 96-well PCR plate for amplification, using the following program: 95 ˚C for 10 min, followed by 40 cycles of 94 ˚C for 30 s and 60 ˚C (*TERT*/*TP53*/*CTNNB1*:121A\>G) or 62 ˚C (*CTNNB1*:133T\>C) for 60 s, followed by 98 ˚C for 10 min, and holding at 4 ˚C. The rate of temperature rise was set at 2.5 ˚C/s. When the amplification was done, the sealed 96-well plate was read with QX200 Droplet Reader (Bio-Rad) using QuantaSoft (Bio-Rad). Mutant allele concentration (copies/µl, C~MUT~) and wild-type allele concentration (copies/µl, C~WT~) were calculated and mutant allele frequency (MAF) was calculated as: MAF = C~MUT~/(C~MUT~+ C~WT~). The primers and probes were synthesized by Sangon Biotech (Shanghai, China) and sequence information was in Table [1](#T1){ref-type="table"}.

Sanger sequencing
-----------------

The frozen primary tumor and matched adjacent liver tissues were obtained in 10 HCC patients and used to extract DNA using DNeasy Blood & Tissue Kit (QIAGEN). For another 31 HCC patients, the formalin-fixed paraffin-embedded (FFPE) tumor and adjacent liver tissues were retrieved and a 8x3 mm cylindrical tissue block was acquired from each FFPE sample to purify DNA using QIAamp DNA FFPE Tissue Kit (QIAGEN). Both the frozen and FFPE tumor tissues were confirmed pathologically to contain more than 50% tumor cell content. Germline DNA was extracted from PBMCs using DNeasy Blood & Tissue Kit in the left seven patients. The PCR products were purified with a MinElute PCR Purification Kit (QIAGEN). The sequencing reactions were set up with 1 μl of purified PCR products using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster, USA) and sequencing was performed on ABI 3730XL DNA sequencer (Applied Biosystems). The investigators who performed Sanger sequencing were blinded to the ddPCR results.

Statistical analysis
--------------------

The mutation concordance rate between plasma and tumor tissues, and the sensitivity and specificity of ddPCR were calculated respectively. The concordance rate was calculated as the number of individuals having the same mutations in both plasma and tumor tissues plus the number of individuals without mutations in neither plasma nor tumor tissues out of the total number of individuals with matched plasma and tumor tissues. The sensitivity, specificity and 95% confidence interval (CI) of ddPCR were calculated by comparing plasma DNA results with those of the paired tumor tissues using Cohen\'s kappa test, as previously reported [@B15]. The statistical analysis was conducted with SPSS version 19.0.

Results
=======

Patients\' demographics
-----------------------

Totally, 48 newly diagnosed HCC patients were included in this study. Table [2](#T2){ref-type="table"} summarized the clinicopathological and epidemiological information. Most of the HCC patients were male (43/48, 89.6%) with the median age being 58 (range, 40-78) years. HBsAg was positive in 39 patients and 40 patients had liver cirrhosis. Before surgery, 26 patients had AFP level above 20 ng/ml and the Child-Pugh Score of all patients were rated A. All patients successfully underwent hepatectomy with curative intention and the Edmonson grades of their tumors were I (1), II (31), III (14), and IV (2); most patients (47) were classified as BCLC (Barcelona Clinic Liver Cancer) stage A.

Detection of circulating mutant DNA in the plasma of HCC patients using ddPCR
-----------------------------------------------------------------------------

Before applying ddPCR to detect ctDNA, we first evaluated the lower of detection (LOD) and working stability of the platform. Through serial dilution of the cfDNA from a patient with known *KRAS* G12D mutation (MAF, 5%; starting concentration, 10 ng/µl), we were able to stably detect this mutant at 1:500 dilution. Although positive signals had also been detected at further dilution of 1:5000, the detected MAF was 0.015%, higher than the theoretical value and it was unknown whether this was caused by dilution error or the inherent limit of the platform (Figure [1](#F1){ref-type="fig"}). Therefore, the LOD of ddPCR platform was set at 0.01% with good reproducibility.

Unlike breast cancer, colorectal cancer, and lung cancer which have hotspot mutations enriched in genes such as *KRAS*, *PIK3CA*, and *EGFR*, HCC has a wide spectrum of genes harboring multiple mutation sites and types. To this regard, we analyzed the results of studies which conducted whole genome/exome sequencing and searched the COSMIC (Catalogue of somatic mutations in cancer) database to find frequently reported mutations. Four mutant sites within three genes, *TP53* (c.747G\>T), *TERT* (c.1-124C\>T), and *CTNNB1* (c.121A\>G) and (c.133T\>C) were identified as recurrent mutant events. These four mutants were chosen as targets in following ddPCR analysis.

We then evaluated the feasibility of detecting these four mutants in cfDNA using ddPCR. The preoperative blood samples were prospectively collected and 1 ml plasma was used to isolate cfDNA. The cfDNA was successfully extracted from each sample and the amount of cfDNA ranged from 0.4 to 3.1 milligram, which was above the detection threshold of concentration. The wild and mutant DNA copies of the four sites in cfDNA were detected and positive reactions were identified by fluorescent intensities; the concentrations of mutant and wild type DNA copies were calculated respectively. Examples of positive ddPCR assays were shown in Figure [2](#F2){ref-type="fig"}. In general, 27 (56.3%) out of the 48 patients were found to have at least one mutant in the plasma: 7 patients were positive for *TP53* (c.747G\>T), with the MAF ranging from 0.33% to 23.2%; 11 patients had detectable *TERT* (c.1-124C\>T) mutants, from 0.55% to 14.3%; *CTNNB1* (c.121A\>G) and (c.133T\>C) were separately identified in 6 patients, ranging from 9.2% to 23.7% and 0.82% to 23.2%, respectively (Table [3](#T3){ref-type="table"}). The MAFs were all higher than the LOD of the ddPCR platform, therefore ruling out the possibility of false positive. In three patients, two mutants were simultaneously detected: *TP53* (c.747G\>T) and *TERT* (c.1-124C\>T) in patient H04 and H41, and *TERT* (c.1-124C\>T), *CTNNB1* (c.121A\>G) in patient H43.

Identification of the circulating mutants\' origin with Sanger sequencing
-------------------------------------------------------------------------

The positive mutants detected in the plasma should not be rashly claimed to be ctDNAs since germline mutations might also be detected in cfDNA. Thus, we sequenced the DNAs of corresponding tumor tissues and matched adjacent liver tissues or PBMCs to identify the origin of these circulating mutants. Sanger sequencing was performed in all samples regardless of mutant status in the cfDNA. Somehow surprisingly, sequencing of the tumor DNA only detected positive mutations in six patients and they all had one mutant validated each, including the patient having two circulating mutants. In two patients (H16 and H19) whose cfDNAs were mutants negative, heterozygous genotype of *TERT* (c.1-124C\>T) and *TP53* (c.747G\>T) were respectively detected in tumor tissues; in patient H6 and H50 who had circulating *CTNNB1* mutants, the tumor tissues were found *TERT* (c.1-124C\>T) positive whereas the genotype of *CTNNB1* were demonstrated to be wild type. Interestingly, none of the mutants were detected in DNAs extracted from adjacent liver tissues or PBMCs, thus excluding germline mutations as the source of these circulating mutants. The concordance rate between plasma and tumor tissues, sensitivity, specificity, and 95% CI of ddPCR assay were shown in Table [4](#T4){ref-type="table"}. Combining together, we could conclude that the mutants detected in the plasma of HCC patients were not derived from germline DNA and were very likely to be acquired as somatic events during the carcinogenesis of liver, which qualified them as ctDNA.

Discussion
==========

Recent evidences demonstrated that ctDNA could be used as liquid biopsy with broad application including early diagnosis, disease progression prediction, and personalized treatment [@B16]. Indeed, ctDNA has been widely reported in different malignancies whereas, on the contrary, it was rarely studied in HCC. Considering the status quo of HCC management, which requires novel strategies for early diagnosis and disease surveillance [@B17], and the trend of precision medicine in oncology [@B18], it\'s necessary to investigate the role of ctDNA in HCC. To the best of our knowledge, this study is the first to evaluate the presence of ctDNA in HCC patients by detecting multiple point mutations using ddPCR.

ctDNAs generally only account for a small fraction (could be lower than 0.01%) of cfDNAs [@B19], which necessitates the employment of highly sensitive detection methods. ddPCR and next generation sequencing (NGS) are currently the most commonly used mutation detection methods. Although there existed limitations including low throughput and the optimization of reaction condition for each mutation of interest, the advantages including low cost, in-house operation, and quick turnaround time of ddPCR made it easily accessible to researchers and clinicians. Moreover, each reaction of ddPCR was performed in individual droplet containing no more than one template, thus enabling absolute quantification of nucleic acids and avoiding the dependency on DNA calibrant in qPCR. Specially, optimal template dilution and droplet partitioning could reduce competitive amplification effects, allowing detection of mutant as low as 0.001%, 1,000 times lower than that in qPCR [@B20].

Successful ctDNA detection also necessitates the selection of tumor-specific gene aberrations. This would be unnecessary for NGS-based methods; however, ddPCR-based methods could only target limited mutants per reaction, even for multiplex ddPCR [@B21]. Thus, hotspot mutations are preferred for identification of ctDNA using ddPCR. Although mutant loci within gene *KRAS*, *PIK3CA*, and *EGFR*have been widely used to identify ctDNA in breast, colorectal and lung cancer [@B21]-[@B23], they were less frequently mutated in HCC [@B24], [@B25]. Therefore, studies which sequenced whole genome/exome and COSMIC database were reviewed to identify genes frequently mutated in HCC [@B26]-[@B31]. Despite discrepancies, three genes, *TP53*, *CTNNB1*, and *TERT* were identified as the top repeatedly mutated ones, with multiple gene loci and mutant type reported, and four sites were selected as candidate targets. The *TP53* is the most commonly mutated gene in HCC and c.747G\>T (R249S) is highly related with HBV infection and Aflatoxin B1 exposure; *CTNNB1* is found mutually exclusive with *TP53* mutation [@B27] and thus would increase mutant detection rate in combination with *TP53*. *TERT* promoter mutation is an early event in liver carcinogenesis and -124C\>T mutation was found positive in about 50% HCC cases [@B32], [@B33]. We found 7 patients were *TP53*mutation positive, and these patients were exclusive of *CTNNB1* mutants as reported. Compared to previous study using serum DNA to detect *TP53* c.747G\>T mutation [@B34], we acquired higher positive rate and this might be explained by the contamination of genomic DNA from blood cells in serum [@B35], which lowered the MAF, and the high sensitivity of ddPCR, which reduced false negative. The result was quite encouraging: circulating plasma mutants could be readily detected by targeting point mutations using ddPCR in HCC and with a panel composed of multiple mutant loci in different genes, more patients might be identified circulating mutant positive.

However, it\'s reasonable to doubt that the circulating mutants are not all derived from tumor cells since germline mutation might also be detected in plasma. We thus screened the tumor samples by Sanger sequencing to identify their origin. Surprisingly, nearly half of the circulating mutants were not detected in tumor tissues while, not unexpectedly, the mutants were not present in any adjacent liver tissues or PBMCs. Considering the sensitivity of our ddPCR platform, the high MAF of circulating mutants, the absence of mutants in germline DNA, and no histories of previous or synchronous malignancy, we suggested that the positive signals in cfDNA were neither false positives nor derived from the nonneoplastic origin, which qualified them as ctDNAs from liver tumor cells. As to the discordance of mutant status between plasma and tumor tissues, intratumor heterogeneity (ITH) might possibly be the underlying reason. Genetically, ITH means different regions within the tumor do not share the same mutational landscape and it\'s widely existed in cancers [@B36]-[@B39], including HCC [@B40]. Under such condition, it was hard to get a full view of the genomics of tumor by single-site sampling [@B41]. Supporting this, studies have reported detection of invalidated mutants in primary tumors by analyzing plasma DNA with ddPCR [@B15] and ctDNA proved to be a potential tool for *de novo* mutation identification, namely capturing ITH [@B42]. Herein, the tumor DNA was only extracted from 25 mg tissues, which accounted for a very small fraction of the whole tumor and would surely simplify the mutant profile. Although four false negative events suggested this ddPCR should be further improved, these results suggested that detecting ctDNA might bear the potential to overcome the limit of ITH and identify rare mutations missed by single-site sampling.

Several limitations should be recognized. The etiology of HCC patients in this study was mainly HBV infection and thus it\'s unclear whether our ddPCR strategy could achieve similar sensitivity to detect ctDNA in HCC patients of other causes. In addition, only four mutations were selected to screen ctDNA and negative results were noted in approximately half of the patients. Multiplex ddPCR might be a feasible solution. Finally, the clinical significance of ctDNA as diagnostic and predictive biomarker in HCC patients should be further evaluated. Further studies aiming at improving the assay sensitivity by using multiple mutations and unveiling the utility of ctDNA using larger sample size and sequential blood sampling are warranted.

Conclusively, we presented herein initial evidence demonstrating the presence of ctDNA in HCC patients and the feasibility of detecting ctDNA using ddPCR. Although the detection rate needs to be increased and the clinical significance should be further evaluated, detection of ctDNA using ddPCR in HCC patients shows the potential as liquid biopsy and might help disease diagnosis and surveillance.
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![Measurement the LOD of ddPCR platform. A, Positive signals (blue dots) from mutant type could be stably detected at 1:500 dilution, at which level the MAF is 0.01%; B, Positive signals (green dots) of wild type DNA at different dilution. Black dots are non-amplification signals. (MAF, mutant allele frequency).](jcav07p1907g001){#F1}

![Representative images of ddPCR analysis results. A, Positive signals of*TP53* 747 G\>T from patient H66 with MAF of 23.2%; B, Positive signals of*TERT*c.1-124 C\>T from patient H32 with MAF of 0.67%; C, Positive signals of*CTNNB1* c.121 A\>G from patient H09 with MAF of 9.2%; D, Positive signals of*CTNNB1* c.133 T\>C from patient H62 with MAF of 13.6%. Green dots are signals from wild type DNA copies, blue dots are signals from mutant DNA copies, orange dots were mixed signals from wild type and mutant DNA copies, and black dots are non-amplification signals. (MAF, mutant allele frequency).](jcav07p1907g002){#F2}

###### 

Sequence information of the primers and probes for the ddPCR assays.

  Mutation             Primer and probe                      Sequence
  -------------------- ------------------------------------- ------------------------------
  TERT (c.1-124C\>T)   Forward primer                        5\'-GTCCTGCCCCTTCACCTT-3\'
  Reverse primer       5\'-CAGCGCTGCCTGAAACTC-3\'            
  Mutant probe         5\'-FAM-AGCCCCCTCTGGG-MGB-3\'         
  Wild type probe      5\'-VIC-AGCCCCCTCCGGG-MGB-3\'         
  CTNNB1 (121A\>G)     Forward primer                        5\'-TCACTGGCAGCAACAGTCTT-3\'
  Reverse primer       5\'-CAGGACTTGGGAGGTATCCA-3\'          
  Mutant probe         5\'-FAM-GTGCCACTGCCAC-MGB-3\'         
  Wild type probe      5\'-VIC-GGTGCCACTACCAC-MGB-3\'        
  CTNNB1 (133 T\>C)    Forward primer                        5\'-TCACTGGCAGCAACAGTCTT-3\'
  Reverse primer       5\'-CAGGACTTGGGAGGTATCCA-3\'          
  Mutant probe         5\'-FAM-GTGCCACTGCCAC-MGB-3\'         
  Wild type probe      5\'-VIC-GGTGCCACTACCAC-MGB-3\'        
  TP53 (c.747G\>T)     Forward primer                        5\'-TGTAACAGTTCCTGCATGG-3\'
  Reverse primer       5\'-TCAGAGGCAAGCAGAGG-3\'             
  Mutant probe         5\'-FAM-CATGAACCGGAGTCCCATC-MGB-3\'   
  Wild type probe      5\'-VIC-CATGAACCGGAGGCCCATC-MGB-3\'   

###### 

Clinical characteristics of enrolled patients.

  Clinical characteristics   No. of patients
  -------------------------- -----------------
  Age, years                 
  ≥ 50                       38
  \< 50                      10
  Gender                     
  Male                       43
  Female                     5
  HBsAg                      
  Positive                   39
  Negative                   9
  Liver cirrhosis            
  Yes                        40
  No                         8
  AFP, ng/ml                 
  ≥ 20                       26
  \< 20                      22
  ALT, U/L                   
  ≥ 75                       16
  \< 75                      32
  No. of tumors              
  Single                     38
  Multiple                   10
  Tumor size                 
  Small HCC                  25
  Large HCC                  23
  Child-Pugh score           
  A                          48
  B                          0
  BCLC stage                 
  A                          47
  B                          1

###### 

Analysis of mutation status in plasma with ddPCR.

  Patient   Mutation fraction (mutant/wild type, copies/μl)                                          
  --------- ------------------------------------------------- ------------------- ------------------ ------------------
  H04       0.33% (0.1/30.3)                                  7.0% (4.3/61.8)     Negative           Negative
  H06       Negative                                          Negative            11.5% (1.9/16.5)   Negative
  H09       Negative                                          Negative            9.2% (1.8/19.6)    Negative
  H10       1.0% (0.1/9.6)                                    Negative            Negative           Negative
  H20       Negative                                          0.55% (0.07/12.8)   Negative           Negative
  H23       Negative                                          7.2% (1.2/16.6)     Negative           Negative
  H32       Negative                                          0.67% (0.07/10.4)   Negative           Negative
  H35       1.8% (0.11/6.2)                                   Negative            Negative           Negative
  H41       3.2% (0.1/3.1)                                    0.89% (0.07/7.9)    Negative           Negative
  H43       Negative                                          0.63% (0.08/12.8)   21.6% (3/13.9)     Negative
  H47       Negative                                          1.4% (0.07/4.9)     Negative           Negative
  H50       Negative                                          Negative            Negative           2.3% (0.34/14.6)
  H51       Negative                                          Negative            18.9% (1.7/9)      Negative
  H52       Negative                                          3.3% (0.08/2.4)     Negative           Negative
  H53       0.55% (0.11/20.1)                                 Negative            Negative           Negative
  H57       Negative                                          Negative            Negative           0.82% (0.1/12.2)
  H58       Negative                                          1.3% (0.07/5.6)     Negative           Negative
  H59       10% (0.6/6)                                       Negative            Negative           Negative
  H61       Negative                                          Negative            Negative           16.5% (1.7/10.3)
  H62       Negative                                          Negative            Negative           13.6% (0.6/4.4)
  H63       Negative                                          Negative            Negative           20.3% (1.6/7.9)
  H65       Negative                                          Negative            Negative           23.2% (2.2/9.5)
  H66       23.2% (1.9/8.2)                                   Negative            Negative           Negative
  H67       Negative                                          Negative            16.8% (6.8/40.4)   Negative
  H68       Negative                                          0.92% (0.08/8.7)    Negative           Negative
  H78       Negative                                          14.3% (0.77/5.4)    Negative           Negative
  H79       Negative                                          Negative            23.7% (11/46.5)    Negative

###### 

Concordance of mutants detected in plasma by ddPCR and their status in paired tumor tissues.

  Plasma DNA             Tumor tissue   Total   Concordance (95% CI)   
  ---------------------- -------------- ------- ---------------------- ---------------------------
  *TP53*(747G\>T)                                                      
  \+                     1              5       6                      85.4% ^\*^ (71.6%-93.1% )
  \-                     1              34      35                     50% (9.5%-90.6%)
  Total                  2              39      41                     87.2% (73.3%-94.4%)
  *TERT* (c.1-124C\>T)                                                 
  \+                     5              5       10                     80.5% ^\*^ (66.0%-89.8%)
  \-                     3              28      31                     62.5% (30.6%-86.3%)
  Total                  8              33      41                     84.9% (69.1%-93.4%)
  *CTNNB1*(c.121A\>G)                                                  
  \+                     0              5       5                      87.8% (74.5%-94.7%)
  \-                     0              36      36                     NA
  Total                  0              41      41                     87.8% (74.5%-94.7%)
  *CTNNB1*(c.133T\>C)                                                  
  \+                     0              5       5                      87.8% (74.5%-94.7%)
  \-                     0              36      36                     NA
  Total                  0              41      41                     87.8% (74.5%-94.7%)

95% CI, 95% confidence interval; \*, *P* \< 0.05; NA, not applicable.
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